GOVX
HEALTHCAREGeoVax Labs Inc
AI Insight
What's Moving GOVX Today?
No stock-specific AI insight has been generated for GOVX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.96$24.50
$1.29
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-13.82
Dividend Yield—
Dividend / Share—
ROE-509.0%
Profit Margin—
Debt / Equity—
Trading
Volume207K
Avg Volume (10D)—
Shares Outstanding5.2M
GOVX News
25 articles- Form 4 GeoVax Labs Inc For: 22 June By Investing.comInvesting.com Canada·Jun 22, 2026
- GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant CancersYahoo Finance·Jun 17, 2026
- GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowYahoo Finance·Jun 12, 2026
- GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy ResponsesYahoo Finance·Jun 8, 2026
- GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease InnovationYahoo Finance·Jun 3, 2026
- GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat ReadinessYahoo Finance·Jun 1, 2026
- Is Co-Diagnostics National Security’s Next Diagnostic Pick?Marketbeat·May 28, 2026
- Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar EventYahoo Finance·May 27, 2026
- Why Is GOVX Stock Falling Today?Stocktwits·May 26, 2026
- GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)Yahoo Finance·May 26, 2026
- How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding RisksYahoo Finance·May 26, 2026
- WHO Africa Chief Warns It's A 'Big Mistake' To Underestimate Ebola Outbreak As Deadly Virus Spreads Beyond CongoBenzinga·May 23, 2026
- GeoVax Stock Higher As Company Highlights MVA Platform For Ebola ThreatsBenzinga·May 20, 2026
- GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine PlatformsYahoo Finance·May 20, 2026
- GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus ConcernsStocktwits·May 19, 2026
- GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease ThreatsYahoo Finance·May 18, 2026
- GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq RulesThe Globe and Mail·May 18, 2026
- All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to BuyYahoo Finance·May 15, 2026
- GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation PlansYahoo Finance·May 14, 2026
- GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold TumorsYahoo Finance·May 13, 2026
- GeoVax (Nasdaq: GOVX) raises $595K, adds new warrant packageStock Titan·May 8, 2026
- GeoVax Announces a Warrant Inducement TransactionThe Globe and Mail·May 7, 2026
- GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging PathwayYahoo Finance·May 6, 2026
- GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership OpportunitiesYahoo Finance·Apr 29, 2026
- GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer TherapiesYahoo Finance·Apr 27, 2026
All 25 articles loaded
Price Data
Open$1.27
Previous Close$1.29
Day High$1.35
Day Low$1.26
52 Week High$24.50
52 Week Low$0.96
52-Week Range
$0.96$24.50
$1.29
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-13.82
Dividend Yield—
Dividend / Share—
ROE-509.0%
Profit Margin—
Debt / Equity—
Trading
Volume207K
Avg Volume (10D)—
Shares Outstanding5.2M
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. The company is headquartered in Smyrna, Georgia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—